Raf kinases are a family of three serine/threonine-specific protein kinases that are related to retroviral oncogenes.Rapidly Accelerated Fibrosarcoma is referred to as RAF. The RAS-RAF-MEK-ERK signal transduction cascade, also known as the mitogen-activated protein kinase (MAPK) cascade, involves Raf kinases. Interaction with RAS-GTPases is necessary for RAF kinase activation. A-RAF, B-RAF, and C-RAF (Raf-1) are the three members of the RAF kinase family. The B-Raf protein is involved in transmitting signals within cells that control cell growth.It was demonstrated that it was flawed (mutated) in a few human cancers. The RAF1 gene in humans encodes the enzyme C-RAF, also known as Raf-1. The c-Raf protein is a MAP kinase kinase (MAP3K) that works after the Ras subfamily of membrane-associated GTPases. It is a component of the ERK1/2 pathway. C-Raf is a member of the TKL (Tyrosine-kinase-like) group of protein kinases and belongs to the Raf kinase family of serine/threonine-specific protein kinases.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V50935 | (Z)-GW-5074 | 1233748-60-1 | c-Raf inhibitor |
|
V2761 | AD80 | 1384071-99-1 | AD80 is a novel multikinase inhibitor that shows strong activity against human RET, BRAF, S6K, and SRC but were much less active than either AD57 or AD58 against mTOR. |
|
V1013 | Agerafenib (CEP-32496; RXDX-105; AC013773) | 1188910-76-0 | Agerafenib (formerly RXDX105; AC013773;RXDX-105;CEP-32496;AC-01377)is a potent and orally bioactive inhibitor of BRAFV600E and c-Raf with potential antitumor activity. |
|
V1006 | AZ 628 (AZ-628; AZ628) | 878739-06-1 | AZ-628 (AZ628; AZ 628) is a novel, selective, and orally bioavailable Raf inhibitor with potential antineoplastic activity. |
|
V74131 | B-Raf IN 13 | 2573782-74-6 | B-Raf IN 13 is a BRAF inhibitor (antagonist) with IC50 of 3.55 nM in the BRAF V600E enzyme assay. |
|
V74141 | B-Raf IN 14 | 326918-98-3 | B-Raf IN 14 (Comp 25) is a BRAF inhibitor (antagonist) with IC50 of 11.08 μM and may be utilized in cancer-related research. |
|
V74147 | B-Raf IN 16 | 2304746-24-3 | B-Raf IN 16 (Compound I) is a BRAF inhibitor belonging to the cyclic iminopyrimidine analogues. |
|
V74133 | B-Raf IN 2 | 2649372-20-1 | B-Raf IN 2 is a potent and specific BRAF inhibitor for cancer-related research. |
|
V3442 | B-Raf inhibitor 1 | 1093100-40-3 | B-Raf inhibitor 1 is a novel, potent and selectiveRafkinase inhibitor withKis of 1 nM, 1 nM, and 0.3 nM for B-RafWT, B-RafV600E, and C-Raf, respectively. |
|
V8230 | Belvarafenib (GDC-5573, HM-95573, RG-6185) | 1446113-23-0 | Belvarafenib (GDC-5573, HM95573, RG6185) is a novel, potent and selective inhibitor of the RAF (Rapidly Accelerated Fibrosarcoma) family kinases with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively. |
|
V74139 | Belvarafenib TFA (HM95573 TFA; GDC-5573 TFA; RG6185 TFA) | 2443966-84-3 | Belvarafenib TFA (HM95573 TFA) is a potent, broad inhibitor of rapidly accelerating fibrosarcoma kinase (RAF) with IC50s of 56 nM, 7 nM and C-RAF for B-RAF, B-RAFv600E and C-RAF, respectively. |
|
V4710 | BI-882370 | 1392429-79-6 | BI-882370 (BI 882370), structurally similar to vermurafenib, is a novel, highly potent and selective BRAF inhibitor with anticancer activity. |
|
V2661 | CCT196969 | 1163719-56-9 | CCT196969 (CCT-196969) is a novel, orally bioavailable, pan-RAF inhibitor (IC50 = 0.1 μM) with anti-SRC and anticancer activity. |
|
V6701 | CID-25014542 | 220904-99-4 | Raf inhibitor 2 is a potent raf kinase inhibitor (IC50<1.0 μM), compound 32, developed from EP1003721B1 patent. |
|
V1004 | Dabrafenib (GSK2118436) | 1195765-45-7 | Dabrafenib (formerly known as GSK2118436; GSK-2118436; GSK-2118436A; GSK-2118436B. Trade name: Tafinlar) is a novel, specific, orally bioavailable inhibitor of BRAF V600 mutants with potential anticancer activity. |
|
V3634 | Dabrafenib mesylate | 1195768-06-9 | Dabrafenib mesylate (formerly GSK-2118436 mesylate; Tafinlar), themesylate salt of dabrafenib, is an orally bioavailable BRAF V600 inhibitor that has been approved in 2013 by FDA to treat melanoma. |
|
V74145 | Dabrafenib-d9 (GSK2118436A-d9; GSK2118436-d9) | 1423119-98-5 | Dabrafenib-d9 is the deuterated form of dabrafenib. |
|
V1014 | Encorafenib (LGX818) | 1269440-17-6 | Encorafenib (formerly LGX818; LGX-818; trade name Braftovi), an approved anticancer drug, is a highly potent, and orally bioavailable B-RAFV600E inhibitor with potential antineoplastic activity. |
|
V79297 | Encorafenib-13C,d3 (LGX818-13C,d3) | Encorafenib-13C,d3 is a 13C- and deuterated-labeled encorafenib. | |
|
V74144 | Everafenib | 2923700-82-5 | Everafenib is a potent and BBB (blood-brain barrier) permeable (penetrable) BRAF inhibitor that also inhibits the MAPK pathway. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
